drugset / Trial / NCT00648882

Fasting Study of Levothyroxine Sodium Tablets 300 mcg to Synthroid® Tablets 300 mcg

NCT00648882

Phase 1 Completed 33 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan's levothyroxine sodium 300 mcg tablets to Abbott's Synthroid® 300 mcg tablets following a single, oral 600 mcg dose (2 × 300 mcg) administered under fasting conditions.

Timeline

Start
2007-03
Primary completion
2007-04
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Levothyroxine Other / unclassified 600 ug Oral

Indications

No indication recorded.